Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding

Keywords

Antibody-dependent cell-mediated cytotoxicity, Fragment crystallizable region, Antibody, Cytotoxicity, Isotype

References

• Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing.Farika Listyani — 2002
• Neutrophils in antibody-based immunotherapy of cancerАнастасия Геннадьевна Ловидова — 2008
• Metabolic properties of human IgA subclasses.A Morell, F Skvaril, G Noseda — 1973
• Enhancement of polymorphonuclear cell-mediated tumor cell killing on simultaneous engagement of fcgammaRI (CD64) and fcalphaRI (CD89).Marjolein van Egmond, Annemiek B. van Spriel, Hans Vermeulen — 2001
• The intriguing role of polymorphonuclear neutrophils in antitumor reactions.Emma Di Carlo, Guido Forni, Pier‐Luigi Lollini — 2001
• Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activityPablo Umaña, Joël Joan Pierre Jean-Mairet, Radmila Moudry — 1999
• Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.Elizabeth Bruckheimer, Christine Fazenbaker, Sandra Gallagher — 2009
• IgG effector mechanisms.Mike Clark — 1996
• FcαRI-positive liver Kupffer cells: Reappraisal of the function of immunoglobulin A in immunityMarjolein van Egmond, E. van Garderen, Annemiek B. van Spriel — 2000
• A Novel Human IgA Monoclonal Antibody Protects against TuberculosisSucharitha Balu, Rajko Reljić, Melanie J. Lewis — 2011
• Antibodies and cancer therapy: versatile platforms for cancer immunotherapyLouis M. Weiner, Rishi Surana, Shangzi Wang — 2010
• Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functionsGregory L. Moore, Hsing Chen, Sher Karki — 2010
• The IgA system: a comparison of structure and function in different species.Veerle Snoeck, Iain R. Peters, Eric Cox — 2006
• Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcγRIIa affinity and selectivity.Sang Taek Jung, William Kelton, Tae Hyun Kang — 2013
• The surface membrane antigen phenotype of human blood basophilsWolfgang Füreder, Hermine Agis, Wolfgang R. Sperr — 1994
• Hybrid IgA2/IgG1 antibodies with tailor-made effector functions.Koteswara R. Chintalacharuvu, Linh-Uyen C. Vuong, Linh A. Loi — 2001
• Immunoglobulin A: Fc(alpha)RI interactions induce neutrophil migration through release of leukotriene B4.Lydia van der Steen, Cornelis W. Tuk, Jantine E. Bakema — 2009
• Cellular distribution, regulation, and biochemical nature of an Fc alpha receptor in humansRenato C. Monteiro, Hiromi Kubagawa, M D Cooper — 1990
• IgGA: a "cross-isotype" engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions.William Kelton, Nishant Mehta, Wissam Charab — 2014
• The human Fc receptor for IgA (Fc alpha RI, CD89) on transgenic peritoneal macrophages triggers phagocytosis and tumor cell lysis.Marjolein van Egmond, A. J. Hanneke van Vuuren, Jan G. J. van de Winkel — 1999

Cited by

• The era of the immunoglobulin A Fc receptor FcαRI; its function and potential as target in diseaseEsil Aleyd, Marieke H. Heineke, Marjolein van Egmond — 2015
• A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgAGerard Rouwendal, Miranda MC van der Lee, Saskia Meyer — 2016
• Immunoglobulin isotype knowledge and application to Fc engineering.Randall J. Brezski, George Georgiou — 2016
• Successive site translocating inoculation potentiates DNA/recombinant vaccinia vaccinationYanqin Ren, Na Wang, Weiguo Hu — 2015
• Enhancement of Immune Effector Functions by Modulating IgG’s Intrinsic Affinity for Target AntigenYariv Mazor, Chunning Yang, M. Jack Borrok — 2016
• Neutrophils in cancerLouise W. Treffers, Ida H. Hiemstra, Taco W. Kuijpers — 2016
• Immunoglobulin A: magic bullet or Trojan horse?Marieke H. Heineke, Marjolein van Egmond — 2017
• Enhancement of antibody functions through Fc multiplicationsQun Wang, Yan Chen, Mark Pelletier — 2017
• Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivoBingyu Li, Lijun Xu, Fei Tao — 2017
• Antibody-Based Cancer Therapy: Successful Agents and Novel Approaches.Djoke Hendriks, Goda Choi, Marco de Bruyn — 2017
• Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High YieldsKristina M. Ilieva, Judit Fazekas, Daniela Achkova — 2017
• Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?Michael J. Marshall, Richard J Stopforth, Mark S. Cragg — 2017
• Use of Monoclonal Antibodies to Prevent the Sexual Transmission of Human Immunodeficiency Virus Type 1Deborah J. Anderson, Joseph A. Politch, Gabriela Baldeon Vaca — 2019
• Monoclonal antibody‐mediated killing of tumour cells by neutrophilsNiels Heemskerk, Marjolein van Egmond — 2018
• Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid TumorsGaurav Nayyar, Yaya Chu, Mitchell S. Cairo — 2019
• Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgGArianne M. Brandsma, Sina Bondza, Mitchell Evers — 2019
• Production, characterization, and in vivo half-life extension of polymeric IgA molecules in miceT. Noelle Lombana, Sharmila Rajan, Julie A. Zorn — 2019
• Considerations for the Design of Antibody-Based TherapeuticsDennis R. Goulet, William M. Atkins — 2019
• Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-LifeKevin O. Saunders — 2019
• IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47–SIRPα Checkpoint InhibitionLouise W. Treffers, Toine ten Broeke, Thies Rösner — 2019

Related papers

• Activity of Two Types of Fc Receptors, FcγRI and FcγRII, in Human Monocyte Cytotoxicity to Sensitized ErythrocytesJan G. J. van de Winkel, G. J. J. C. Boonen, P. L. W. JANSSEN — 1989
• Asymmetrical Fc Engineering Greatly Enhances Antibody-dependent Cellular Cytotoxicity (ADCC) Effector Function and Stability of the Modified Antibodies*Zhi Liu, Kannan Gunasekaran, Wei Wang — 2013
• The Dual Targeting of FcRn and FcγRs via Monomeric Fc Fragments Results in Strong Inhibition of IgG-Dependent Autoimmune PathologiesCéline Monnet, Émilie Jacque, Christophe de Romeuf — 2021
• High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR*Robert L. Shields, Angela K. Namenuk, Kyu Hong — 2001
• IgG2m4, an engineered antibody isotype with reduced Fc functionZhiqiang An, Gail Forrest, Renée Moore — 2009
• Structural Characterization of GASDALIE Fc Bound to the Activating Fc receptor FcγRIIIaAlysia A. Ahmed, Sravya Keremane, Jost Vielmetter — 2016
• Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptorsStephen L. Sazinsky, René G. Ott, Nathaniel W. Silver — 2008
• Structure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG bindingJinghua Lu, Jonathan Chu, Zhongcheng Zou — 2015
• Functional, Biophysical, and Structural Characterization of Human IgG1 and IgG4 Fc Variants with Ablated Immune FunctionalitySusan H. Tam, Stephen G. McCarthy, Anthony Armstrong — 2017